KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc., a leader in AI-powered blood tests for cardiovascular diagnostics, announces that the United States Patent and Trademark Office has issued a patent for its highly accurate blood test, HART CADhs, which assesses a patient’s risk of obstructive coronary artery disease, also referred to as obstructive heart disease. The company utilized its Artificial Intelligence (AI)-driven HART platform and expertise in cardiac blood tests to develop HART CADhs.
“Prevencio is pleased with the advancement of our patent portfolio, which is crucial for maintaining our competitive advantage,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. “This is the fourth patent issued for our novel AI-driven, multiple protein blood tests. We have several more patents pending.”
In research conducted with Massachusetts General Hospital, HART CADhs demonstrated an 86% AUC accuracy, outperforming standard-of-care tests such as exercise, echocardiography and nuclear stress tests which collectively had an accuracy of 52% AUC.
Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association (AHA), the U.S. spends approximately $318 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, AHA projects that 45% of the U.S. adult population will have cardiovascular disease, with healthcare-related expenditures exceeding $1 trillion.
Rhyne added, “Given the cost, complexity, and pervasiveness of cardiovascular disease, our highly accurate and accessible HART blood tests are well-positioned to improve patient outcomes while reducing costs.”
In addition to the HART CADhs test for diagnosing heart artery obstruction, Prevencio offers a second multi-protein blood test, HART CVE, which assesses one-year risk of a heart attack, stroke or cardiovascular death. HART CADhs and HART CVE tests are currently available to medical professionals for patient use. For additional information, visit Prevencio, Inc.
About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics for diagnostic, medical device and pharmaceutical companies. Using this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.
For additional information, visit Prevencio.
HART test results have been peer-reviewed published 34 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; Pediatric Academic Societies International Sessions; International Spinal Cord Society Scientific Sessions; ASTRO Scientific Sessions; Transcatheter Cardiovascular Therapeutics Sessions; American Society of Clinical Oncology Genitourinary; and International Kawasaki Disease Symposium) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Open Heart; Biomarkers in Medicine; Journal of American Heart Association; European Journal of Preventive Cardiology; and International Journal of Cardiology).
About Prevencio, Inc.
Prevencio's value proposition is "Power of AI to Prevent the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease & beyond. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic risk scores and coronary artery calcium. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The company does not undertake to update disclosures contained in this press release.
